Previous 10 | Next 10 |
Calliditas Therapeutics (NASDAQ:CALT) +67%. Recursion Pharmaceuticals (NASDAQ:RXRX) +10%. Verrica Pharmaceuticals (NASDAQ:VRCA) +9%. Qorvo (NASDAQ:QRVO) +6%. Sharecare (NASDAQ:SHCR) +5%. Blue Bird (NASDAQ:BLBD) -10%. Freshworks (NASDAQ:FRSH) -4%. Nutanix (NASDAQ:NTNX) -4%. Cumberland Pharmace...
FDA grants Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy - TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to reduce proteinuria in adults with primary IgA nephropathy...
Calliditas Therapeutics (NASDAQ:CALT) ADRs have climbed in the post-market after the company announced the FDA approval of TARPEYO (budesonide) to address proteinuria in adults with primary immunoglobulin A nephropathy ((IgAN)). FDA clearance for TARPEYO delayed-release capsules tra...
Calliditas Therapeutics: Interim Report Q3, 2021 A quarter of deal making and regulatory review PR Newswire STOCKHOLM , Nov. 18, 2021 /PRNewswire/ -- "Following on from the positive top line read out of Part A our Phase 3 study, we initiated a structured proc...
Calliditas announces poster presentations at ASN Digital Kidney Week 2021 PR Newswire STOCKHOLM , Nov. 3, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced upcoming presentations concerning N...
Gainers: Kiniksa Pharmaceuticals (NASDAQ:KNSA) +13%, Ocugen (NASDAQ:OCGN) +13%, Calliditas Therapeutics (NASDAQ:CALT) +11%, Context Therapeutics (NASDAQ:CNTX) +10%, Bone Biologics (OTCPK:BBLG) +7%. Losers: ABVC BioPharma (NASDAQ:ABVC) -32%, Semler ...
Calliditas Therapeutics' nomination committee for the AGM 2022 PR Newswire STOCKHOLM , Nov. 2, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2022. The nomination committee, whic...
Gainers: Cadence Bancorporation (NYSE:CADE) +43%. A10 Networks ATEN +30%. GH Research (NASDAQ:GHRS) +25%. Retail Value (NYSE:RVI) +23%. WiMi Hologram WIMI +23%. Greenidge (NASDAQ:GREE) +19%. Aspen Aerogels ASPN +18%. Bel Fuse BELFB +18%. Ramaco Resources (NASDAQ:METC) +16%...
Gainers: G Medical Innovations (NASDAQ:GMVD) +15%, Accuray (NASDAQ:ARAY) +14%, Xeris Biopharma (NASDAQ:XERS) +9%, DURECT (NASDAQ:DRRX) +9%, Ocugen (NASDAQ:OCGN) +7%. Losers: CareDx (NASDAQ:CDNA) -25%, 4D Molecular Therapeutics (NASDAQ:FDMT) -2...
Calliditas announces acquisition of remaining Genkyotex minority shares PR Newswire STOCKHOLM , Oct. 7, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company now controls 100...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Ca...
Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis PR Newswire STOCKHOLM , July 26, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) ( STOCKHOLM : CALTX) ("Calliditas") today announced that the Pha...
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...